MX2019009537A - Potenciadores del receptor de acido alfa-amino-3-hidroxi-5-metil-4 -isoxazol propionico (ampa). - Google Patents

Potenciadores del receptor de acido alfa-amino-3-hidroxi-5-metil-4 -isoxazol propionico (ampa).

Info

Publication number
MX2019009537A
MX2019009537A MX2019009537A MX2019009537A MX2019009537A MX 2019009537 A MX2019009537 A MX 2019009537A MX 2019009537 A MX2019009537 A MX 2019009537A MX 2019009537 A MX2019009537 A MX 2019009537A MX 2019009537 A MX2019009537 A MX 2019009537A
Authority
MX
Mexico
Prior art keywords
compounds
ampa receptor
disorders
treatment
receptor potentiators
Prior art date
Application number
MX2019009537A
Other languages
English (en)
Spanish (es)
Inventor
Ward Simon
Beswick Paul
Pennicott Lewis
Reuillon Tristan
Original Assignee
Univ College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ College Cardiff Consultants Ltd filed Critical Univ College Cardiff Consultants Ltd
Publication of MX2019009537A publication Critical patent/MX2019009537A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MX2019009537A 2017-02-10 2018-02-09 Potenciadores del receptor de acido alfa-amino-3-hidroxi-5-metil-4 -isoxazol propionico (ampa). MX2019009537A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1702221.1A GB201702221D0 (en) 2017-02-10 2017-02-10 Compounds
PCT/GB2018/050370 WO2018146486A1 (en) 2017-02-10 2018-02-09 Ampa receptor potentiators

Publications (1)

Publication Number Publication Date
MX2019009537A true MX2019009537A (es) 2019-10-04

Family

ID=58462168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009537A MX2019009537A (es) 2017-02-10 2018-02-09 Potenciadores del receptor de acido alfa-amino-3-hidroxi-5-metil-4 -isoxazol propionico (ampa).

Country Status (12)

Country Link
US (1) US11186567B2 (https=)
EP (1) EP3580213B1 (https=)
JP (1) JP7014808B2 (https=)
KR (1) KR102665887B1 (https=)
CN (1) CN110520418B (https=)
AU (1) AU2018218307C1 (https=)
ES (1) ES2974824T3 (https=)
GB (1) GB201702221D0 (https=)
MX (1) MX2019009537A (https=)
NZ (1) NZ755747A (https=)
RU (1) RU2019126574A (https=)
WO (1) WO2018146486A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds
CN121487750A (zh) * 2023-06-15 2026-02-06 上海魁特迪生物科技有限公司 Dir结合剂及其用途
CN121652294A (zh) * 2026-02-06 2026-03-13 首都医科大学宣武医院 一种用于检测抗ampar1抗体的融合蛋白及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW575561B (en) 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
IL152848A0 (en) 2000-06-12 2003-06-24 Eisai Co Ltd 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
AU2003302027A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
JP5289043B2 (ja) 2005-04-12 2013-09-11 ヴィコール・ファルマ・アーベー 新規な三環系アンジオテンシンiiアゴニスト
CA2646585A1 (en) 2006-03-20 2007-09-27 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
EP2049475B1 (en) 2006-04-24 2012-02-01 Eli Lilly & Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
TW200817385A (en) 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
DE602007013450D1 (de) * 2006-11-03 2011-05-05 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
GB0711089D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0711088D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
EP2183228B1 (en) 2007-07-26 2014-08-20 Vitae Pharmaceuticals, Inc. CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1
KR20100063087A (ko) 2007-09-20 2010-06-10 코텍스 파마슈티칼스, 인크. 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논
GB0721094D0 (en) 2007-10-26 2007-12-05 Glaxo Group Ltd Compounds
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
AR071236A1 (es) 2008-05-01 2010-06-02 Vitae Pharmaceuticals Inc Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
TW201031649A (en) 2008-12-02 2010-09-01 Organon Nv 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
AP3066A (en) 2009-06-26 2014-12-31 Pfizer Heterocyclic sulfonamides, uses and pharmaceuticalcompositions thereof
WO2011132051A2 (en) 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Tricycle compounds as phosphodiesterase-10 inhibitors
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Also Published As

Publication number Publication date
EP3580213A1 (en) 2019-12-18
RU2019126574A3 (https=) 2021-03-29
JP7014808B2 (ja) 2022-02-01
KR20190117549A (ko) 2019-10-16
GB201702221D0 (en) 2017-03-29
AU2018218307C1 (en) 2022-06-23
KR102665887B1 (ko) 2024-05-10
RU2019126574A (ru) 2021-03-10
WO2018146486A1 (en) 2018-08-16
ES2974824T3 (es) 2024-07-01
CA3051647A1 (en) 2018-08-16
EP3580213C0 (en) 2024-03-27
AU2018218307A1 (en) 2019-08-15
EP3580213B1 (en) 2024-03-27
US11186567B2 (en) 2021-11-30
BR112019016603A2 (pt) 2020-03-31
CN110520418A (zh) 2019-11-29
NZ755747A (en) 2022-02-25
AU2018218307B2 (en) 2022-02-24
JP2020507592A (ja) 2020-03-12
CN110520418B (zh) 2022-08-16
US20210139463A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
PH12016501570B1 (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
GEAP202014908A (en) Allosteric modulators of nicotinic acetylcholine receptors
PH12016501791A1 (en) Muscarinic receptor agonists
JO3316B1 (ar) مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
GEAP201814515A (en) 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
GEAP202115340A (en) Pyrimidine compound as jak kinase inhibitor
CL2018001085A1 (es) Derivados de indolin-2-ona
MX2019009537A (es) Potenciadores del receptor de acido alfa-amino-3-hidroxi-5-metil-4 -isoxazol propionico (ampa).
MY201535A (en) Therapeutic compounds
PH12016501393A1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
ZA202001295B (en) Thiazolopyridine derivatives as adenosine receptor antagonists
MX2014000963A (es) Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.
MX2018014185A (es) Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa.
MX2020009097A (es) Compuestos que modulan la funcion del receptor de ampa.
MX2018004256A (es) Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
MX2017015300A (es) Derivados de aminoesteres.
PH12017501209A1 (en) Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors
PH12019550251A1 (en) HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS
GB2519470A (en) Bicyclic aza compounds as muscarinic M1 receptor agonists
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores
MX2017007648A (es) Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo.